Up 752% in one year! This roaring ASX AI stock just hit all-time highs on major revenue milestone

Investors in Artrya Ltd (ASX: AYA) have been on a whirlwind ride in recent months.

Barely one year ago, shares in this ASX AI stock were changing hands at $0.46 apiece.

Today, Artrya shares reached a new all-time high of $4.29 in morning trade before easing back to $3.92 apiece at the time of writing.

This powerful rally represents a staggering 752% return in just twelve months, blowing the broader market out of the water.

For context, the All Ordinaries Index (ASX: XAO) has risen by 4.53% over the same timeframe.

So, what's behind this remarkable performance?

Let's take a closer look at what's driving the heat for this ASX AI stock.

Improving heart disease diagnostics

Founded in 2019, Artrya is a medical technology company commercialising cloud-based AI solutions for heart disease diagnostics.

Its flagship platform, Salix, provides rapid assessment of chest pain across emergency and primary care settings.

Management believes Salix can improve patient outcomes, lower treatment costs, and streamline clinical workflows.

A major catalyst arrived in August when Artrya secured regulatory approval from the US Food and Drug Administration (FDA) for its Salix Coronary Plaque module.

This milestone followed earlier FDA consent for its Salix Coronary Anatomy product.

These formal ticks of approval paved the way for Artrya to pursue entry into the lucrative American market.

Here, the ASX AI stock is targeting a US market opportunity estimated at US$4.4 billion.

And its commercialisation push appears to be gaining traction.

What happened?

Today, Artrya announced it has now achieved its first revenue from the Salix Coronary Plaque module.

More specifically, US-based Tanner Health has commenced commercial use of the module, generating maiden fee-per-scan revenues for Artrya.

Tanner Health is a community-focused healthcare network serving west Georgia and east Alabama with five hospitals and several practices.

The organisation has now activated the module at its primary hospital in Georgia, with a wider roll-out to further hospitals expected soon.

Artrya Co-Founder and Chief Executive Officer, John Konstantopoulos, stated:

We are thrilled to commence the first clinical use of the Salix® Coronary Plaque module at Tanner Health, which has been well supported by our new U.S. Customer Support team. The ease of activation within the Salix® Coronary Anatomy platform has been well received by the clinicians and the back end processes through to billing are also now established. We look forward to growing adoption across the entire Tanner Health network in the near term, which will generate an attractive ongoing fee to Artrya, from each scan they assess.

What else?

Today's news follows another significant step in Artrya's US expansion.

Last week, shares in the ASX AI stock jumped sharply after unveiling a three-year commercial agreement with Northeast Georgia Health System.

This deal carries a minimum value of US$0.3 million, with further fee-per-scan revenue expected from the Coronary Plaque module and, pending FDA clearance, the Salix Coronary Flow module.

The post Up 752% in one year! This roaring ASX AI stock just hit all-time highs on major revenue milestone appeared first on The Motley Fool Australia.

Motley Fool contributor Bart Bogacz has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2025